Swedish Orphan Biovitrum AB (publ) operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Swedish Orphan Biovitrum AB (publ) with three other
pharmaceutical manufacturers in Europe:
of the United Kingdom
sales of £570.50 million [US$746.73 million]
of which 38%
was Interventional Medicine),
(639.38 million Euro [US$746.07 million]
of which 71%
was Own Network (Spain)), and
based in France
(617.54 million Euro [US$720.58 million]
of which 50%
was Non-Proprietary Homeopathic Medicines).
Swedish Orphan Biovitrum AB (publ) reported sales of SEK 6.51 billion (US$720.49 million)
December of 2017.
increase of 44.8%
versus 2016, when the company's sales were SEK 4.50 billion.
Sales at Swedish Orphan Biovitrum AB (publ) have increased during each of the previous five years
(and since 2012, sales have increased a total of 239%).